[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"asymptomatic-condition\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:asymptomatic-condition":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,74,102],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100644595","effect-of-osteopathic-technique-on-maximum-mouth-opening-width-masseter-muscle-tone-and-stiffness-100644595",false,"NCT07670832","Effect of Osteopathic Technique on Maximum Mouth Opening Width, Masseter Muscle Tone and Stiffness","Effect of Temporomandibular Joint Compression and Decompression Technique on Maximum Mouth Opening Width, Masseter Muscle Tone and Stiffness: A Randomized Controlled Study","Inclusion Criteria:\n\n* Asymptomatic adults that signed the informed consent\n* Functional dentition\n* Preserved masticatory function\n\nExclusion Criteria:\n\n* Diagnosis of inflammatory systemic disorders\n* Diagnosis of cardiovascular disorders\n* Diagnosis of respiratory disorders\n* Diagnosis of central nervous system disorders\n* Diagnosis of rheumatic disorders\n* Visual disturbance affecting balance or proprioception",true,"ALL","18 Years",{"count":20,"type":21},32,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to assess the effect of compression and decompression thecnique on the temporomandibular joint on maximum mouth opening width, masseter muscle tone and stiffness in asymptomatic adults, compared with a control condition consisting of cranial listening touch without therapeutic intent. Evaluations will be conducted immediately after the intervention and one week later.",[27],"Asymptomatic Condition",[29,30,31,32,33,34],"Masseter","Maximum Mouth opening Width","muscle tone","TMJ","Temporomandibular joint","stiffness","NOT_YET_RECRUITING","2026-06-25",{"date":38,"type":39},"2026-06-29","ACTUAL",{"date":41,"type":21},"2026-06",{"date":43,"type":21},"2026-09",{"name":45,"class":46},"Escola Superior de Tecnologia da Saúde do Porto","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100574938","cardiovascular-screening-in-asymptomatic-south-asians-100574938","NCT06765785","Cardiovascular Screening in Asymptomatic South Asians","Cardiovascular Screening in Asymptomatic South Asians - a Pilot Randomized Comparison of Q-risk 3 Score Versus Computed Tomography Coronary Angiography (CTCA)","Inclusion Criteria:\n\n* Asymptomatic South Asian patients of age\n\n  * men≥30 years ≤60 years\n  * Women \\>50 years ≤60 years\n\nPlus at least one of the following risk factors:\n\n* hypertension (HTN)\n* diabetes mellitus (DM)\n* hyperlipidaemia\n* family history of premature coronary artery disease (male \\\u003C45 years, female \\\u003C55 years)\n* smoking (current or ex-smoker in the last 3 months)\n\nExclusion Criteria:\n\n* Patients meeting any of the following criteria will be excluded\n\n  * Patients unable to give written informed consent\n  * History of previous coronary events\u002FCABG\u002F coronary stenting or CTCA in the last 4 years\n  * Patients with pre-existing cardiac symptoms\n  * Patients who could or are pregnant\n  * Allergy to iodine contrast\n  * Active ongoing malignancy and treatment for the same\n  * eGFR ≤30ml\u002Fmin\u002F1.72m2\n  * Participation in any other interventional research trial","30 Years","60 Years",{"count":58,"type":21},50,[24],"Cardiovascular disease (CVD) is the leading cause of morbidity, mortality and healthcare costs in the United Kingdom. Ethnic minorities like South Asians (SA) have a 3-5 times higher incidence of CVD as predicted by various risk scores despite similar or fewer traditional cardiovascular risk factors.\n\nComputed Tomography Coronary Angiography (CTCA) is able to outline the coronary anatomy determining the site, severity and type of atherosclerotic plaque location in the heart arteries. The National Institute for Health and Care Excellence (NICE) guidelines recommends CTCA as the first line investigation for stable chest pain considered to be coming from the heart (angina).\n\nHowever there is no pathway for the patients who are asymptomatic but at high risk of CVD, such as the SA cohort. Current practice involves using risk scores to guide management of asymptomatic adults. One recommended and commonly used score is the Q-risk score (the QRISK ® 3-2018 risk calculatorhttps:\u002F\u002Fqrisk.org \\> three). This score incorporates ethnicity amongst other risk factors and patients with a risk ≥10% of having a heart attack or stroke in the next 10 years are offered primary prevention treatment with low dose statin therapy. For example, an average (height 164cm weight 70kg) 40 year old male of SA descent, without symptoms who is a non-smoker but with Diabetes Mellitus (DM) on tablet treatment scores 5.8% - this risk is not high enough to warrant treatment with a statin unless he also has abnormally raised cholesterol levels. But this patient is still high risk of CVD due to his ethnicity and DM. There is no current evidence to tailor treatment in such asymptomatic, high risk ethnic minorities.\n\nSimilar to screening programs for cancer, screening CTCA, compared to risk stratification with the QRISK ® 3 score, may help in risk stratification of a higher proportion of SA patients. 50 asymptomatic SA patients from 2 sites (25 patients each site) with one CV risk factor will be randomised to either Q-risk 3 score or to screening CTCA.",[62,27,63],"Cardiovascular Diseases","South Asian",[63],"2025-01-08",{"date":67,"type":39},"2025-01-10",{"date":69,"type":21},"2024-12-31",{"date":71,"type":21},"2027-07-31",{"name":73,"class":46},"Sandwell & West Birmingham Hospitals NHS Trust",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":47},"100509315","phase-1-a-study-to-determine-safety-tolerability-and-pharmacokinetics-of-different-orally-administered-regimens-of-the-combination-zy19489-ferroquine-in-adult-asymptomatic-plasmodium-falciparum-carriers-100509315","NCT05911828","A Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum Carriers","Phase Ib, Single-center, Randomized, Study to Determine Safety, Tolerability, and Pharmacokinetics of Different Orally Administered Regimens of the Combination ZY19489-Ferroquine in Adult Asymptomatic Plasmodium Falciparum Carriers","ZYFER-1","Inclusion Criteria:\n\n\\- 1. Male and female (non-pregnant, non-lactating) subjects aged between 18 and 55 years old 2. Participant's body weight ≥ 45 kg 3. Evidence of asymptomatic infection with Plasmodium falciparum mono-infection on microscopy with parasite density between 20\u002FµL and 5000\u002FµL.\n\n4\\. Participants should agree to not donate blood from enrolment in the study until end of the follow-up period 5. Ability to swallow oral medication 6. Evidence of written informed consent personally signed and dated by the participant.\n\nSigned informed consent obtained prior to participation in the study. In case of participant unable to read and write or otherwise incapable of signing an informed consent, an impartial witnessed consent shall be obtained. Participants who are willing to and are able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.\n\nExclusion Criteria:\n\n* 1\\. Mixed Plasmodium infection as judged by microscopy. 2. Presence of clinically significant infectious disease or fever (e.g. Body temperature ≥38°C or 100.4°F) within the 14 days prior to enrollment.\n\n  3\\. History of alcohol or drug abuse or positive urine alcohol test or urine drug test.\n\n  4\\. Consumption of beverages or food containing xanthine bases including chocolate, coffee etc. from 48 hours prior to enrollment.\n\n  5\\. Known allergy to the study drugs and to the rescue medications (artemisinin derivatives, lumefantrine) as well as their excipients.\n\n  6\\. History of having received any antimalarial treatment (alone or in combination) during the following periods before screening:\n  1. Piperaquine, mefloquine, naphthoquine or sulfadoxine-pyrimethamine within 6 weeks prior to screening.\n  2. Amodiaquine, chloroquine within 4 weeks prior to screening.\n  3. Any artemisinin derivative (artesunate, artemether or dihydroartemisinin), quinine, lumefantrine or any other anti-malarial treatment or antibiotic with antimalarial activity (including cotrimoxazole, tetracyclines, quinolones and fluoroquinolones and azithromycin) within 14 days prior to screening.\n\n     7\\. Laboratory parameters outside normal range or with clinically relevant abnormalities as per investigator's judgment.\n\n     8\\. Electrolyte levels outside normal range 9. Hematology, clinical chemistry or urinalysis results at screening that were outside of clinically acceptable laboratory ranges and were considered clinically significant by the Investigator.\n\n     10\\. GFR\\\u003C60 ml\u002Fmin. 11. Previous participation in any malaria vaccine study or received malaria vaccine in any other circumstance within 3 months of screening.\n\n     12\\. Participation in other clinical studies within 90 days before screening. 13. Pregnant or nursing (lactating) women. 14. Sexually active participants not willing to take effective contraception measures from enrolment until the last study visit: For female participants, combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner.\n\n     15\\. All male participants not willing to use either true abstinence, barrier method or with their sexual partner, the use of effective means of contraception from enrolment and until the last study visit.\n\n     16\\. Participant who the investigator considers at particular risk of receiving an anti-malarial or of participating in the study.","55 Years",{"count":84,"type":21},36,[86],"PHASE1","Malaria is caused by protozoan parasites of the genus Plasmodium and it is the most important parasitic disease in terms of mortality and morbidity. Estimates of 247 million malaria cases and 619.000 deaths worldwide were reported by WHO for the year 2021 (1). Plasmodium falciparum can lead to severe malaria and accounts for 90% of malaria deaths that mainly occur in children below the age of 5 years in Sub-Saharan Africa.\n\nA simplified treatment regimen, ideally a single-day cure (or at most 2-day dosing regimen), of uncomplicated malaria due to P. falciparum would be the magic in the antimalarial armamentarium. Improving treatment adherence is one of the key factors in reducing mortality and morbidity and also the transmission of malaria, and such a regimen would substantially increase adherence. To find a new non-artemisinin combination therapy with a shorter regimen, ideally, a single-dose cure, with low resistance potential would be the aim. The two compounds tested here are ZY19489, a triaminopyrimidine, and ferroquine (FQ), a next-generation 4-aminoquinoline. Both compounds show unique features in terms of long half-life, and activity against current drug-resistant strains.\n\nTherefore, the main goal of this clinical trial is to assess the safety of the ZY19489-FQ combination given as a 1- or 2-day dose regimen.",[89,27,90],"Uncomplicated Malaria","Falciparum Malaria","RECRUITING","2024-09-27",{"date":94,"type":39},"2024-10-01",{"date":96,"type":39},"2024-08-30",{"date":98,"type":21},"2025-05-30",{"name":100,"class":101},"Zydus Lifesciences Limited","INDUSTRY",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":112,"phases":4,"briefSummary":113,"conditions":114,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":47},"100532610","the-treatment-effect-for-asymptomatic-common-bile-duct-stone-100532610","NCT06215040","The Treatment Effect for Asymptomatic Common Bile Duct Stone","Multicenter Prospective Study for Efficacy of Asymptomatic Common Bile Duct Stone Treatment","Inclusion Criteria:\n\n* diagnosed as common bile duct stone by image modality examination\n* agreement for this study enrollment\n\nExclusion Criteria:\n\n* no definite common bile duct stone by image modality examination\n* symptomatic patients who complain with fever\u002Fabdominal pain that compatible with common bile duct stone related symptom\n* previously diagnosed as pancreatobiliary malignancy\n* previously treated by endoscopic or percutaneous treatment for bile duct stones\n* severe cardio or pulmonary disease\n* pregnancy or possibility of pregnancy\n* who do not agree with study enrollment","85 Years",{"count":111,"type":21},120,"OBSERVATIONAL","This study is prospective, multicenter study for identify the characteristics of asymptomatic common bile duct stones and effectiveness of treatment.",[115,27,116],"Choledocholithiasis","Quality of Life","2024-01-10",{"date":119,"type":39},"2024-01-22",{"date":121,"type":39},"2024-01-02",{"date":123,"type":21},"2028-12-31",{"name":125,"class":46},"Kyungpook National University Hospital"]